| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
M1 muscarinic acetylcholine receptor (mAChR M1).
|
|---|---|
| ln Vitro |
VU0255035 is a highly selective M1 muscarinic acetylcholine receptor antagonist with a Ki of 14.87 nM. It targets the M1 orthosteric site with >75-fold selectivity over other receptor subtypes and is brain-penetrant.
|
| ln Vivo |
In vivo, VU0255035 reduces pilocarpine-induced seizures in mice, demonstrating its ability to block M1 receptor-mediated effects in the central nervous system.
|
| Enzyme Assay |
The compound's binding affinity to M1 receptor is assessed in cell-free radioligand binding assays using membrane preparations from cells expressing recombinant M1 receptors. Competition binding experiments determine the Ki value of 14.87 nM.
|
| Cell Assay |
VU0255035 is evaluated in cell-based functional assays using cells expressing M1 and other muscarinic receptor subtypes. Calcium mobilization or other second messenger assays measure the compound's ability to antagonize agonist-induced receptor activation, confirming its selectivity and competitive nature.
|
| Animal Protocol |
In vivo studies are conducted in mouse models of pilocarpine-induced seizures to assess the compound's CNS activity. VU0255035 is administered systemically, and its ability to reduce seizure activity is measured to confirm M1 receptor antagonism in the brain.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data is available for VU0255035. As a brain-penetrant compound, it crosses the blood-brain barrier, but specific PK parameters such as half-life and bioavailability have not been reported.
|
| Toxicity/Toxicokinetics |
No detailed toxicological data is available for this compound. As a research-grade chemical probe, standard preclinical toxicity assessments have not been published.
|
| References | |
| Additional Infomation |
N-[3-oxo-3-(4-pyridin-4-yl-1-piperazinyl)propyl]-2,1,3-benzothiadiazole-4-sulfonamide is a member of the pyridine and piperazine classes.
VU0255035 has a molecular formula of C18H20N6O3S2 and a molecular weight of 432.52. The compound is a highly selective, competitive, and brain-penetrant muscarinic M1 receptor antagonist used to examine the role of the M1 receptor in diverse situations. It has not advanced to clinical trials and is not FDA-approved. |
| Molecular Formula |
C18H20N6O3S2
|
|---|---|
| Molecular Weight |
432.5198
|
| Exact Mass |
432.104
|
| CAS # |
1135243-19-4
|
| PubChem CID |
24768606
|
| Appearance |
Light yellow to brown solid powder
|
| Boiling Point |
689.3±65.0°C at 760 mmHg
|
| LogP |
2.578
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
659
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WXDHQWPQLKGANZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H20N6O3S2/c25-17(24-12-10-23(11-13-24)14-4-7-19-8-5-14)6-9-20-29(26,27)16-3-1-2-15-18(16)22-28-21-15/h1-5,7-8,20H,6,9-13H2
|
| Chemical Name |
N-[3-oxo-3-(4-pyridin-4-ylpiperazin-1-yl)propyl]-2,1,3-benzothiadiazole-4-sulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~144.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3120 mL | 11.5602 mL | 23.1203 mL | |
| 5 mM | 0.4624 mL | 2.3120 mL | 4.6241 mL | |
| 10 mM | 0.2312 mL | 1.1560 mL | 2.3120 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
